These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16706569)

  • 1. Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review.
    Vijgen SM; Hoogendoorn M; Baan CA; de Wit GA; Limburg W; Feenstra TL
    Pharmacoeconomics; 2006; 24(5):425-41. PubMed ID: 16706569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: A systematic review.
    Rinaldi G; Hijazi A; Haghparast-Bidgoli H
    Diabetes Res Clin Pract; 2020 Apr; 162():108084. PubMed ID: 32061819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Polish Multicenter Study on Diabetes Epidemiology (PMSDE)--1998-2000].
    Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):751-8. PubMed ID: 11928582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services.
    Carande-Kulis VG; Maciosek MV; Briss PA; Teutsch SM; Zaza S; Truman BI; Messonnier ML; Pappaioanou M; Harris JR; Fielding J
    Am J Prev Med; 2000 Jan; 18(1 Suppl):75-91. PubMed ID: 10806980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the burden of diabetes in Poland].
    Kissimova-Skarbek K; Pach D; Płaczkiewicz E; Szurkowska M; Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):867-73. PubMed ID: 11928598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievable cost saving and cost-effective thresholds for diabetes prevention lifestyle interventions in people aged 65 years and older: a single-payer perspective.
    Anderson JM
    J Acad Nutr Diet; 2012 Nov; 112(11):1747-54. PubMed ID: 23102174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of diabetes education.
    Assal JP
    Pharmacoeconomics; 1995; 8 Suppl 1():68-71. PubMed ID: 10159008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodology of the health economic evaluation of the Feel4Diabetes-study.
    Willems R; Pil L; Lambrinou CP; Kivelä J; Wikström K; Gonzalez-Gil EM; De Miguel-Etayo P; Nánási A; Semánová C; Van Stappen V; Cardon G; Tsochev K; Iotova V; Chakarova N; Makrilakis K; Dafoulas G; Timpel P; Schwarz P; Manios Y; Annemans L;
    BMC Endocr Disord; 2020 Mar; 20(Suppl 1):14. PubMed ID: 32164685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of economic evaluations of local authority commissioned preventative public health interventions in overweight and obesity, physical inactivity, alcohol and illicit drugs use and smoking cessation in the United Kingdom.
    White P; Skirrow H; George A; Memon A
    J Public Health (Oxf); 2018 Dec; 40(4):e521-e530. PubMed ID: 29462346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fight against chronic diseases (high blood pressure, stroke, diabetes and cancer) in Pakistan; cost-effective interventions.
    Wasay M; Jabbar A
    J Pak Med Assoc; 2009 Apr; 59(4):196-7. PubMed ID: 19402275
    [No Abstract]   [Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity.
    Forster M; Veerman JL; Barendregt JJ; Vos T
    Int J Obes (Lond); 2011 Aug; 35(8):1071-8. PubMed ID: 21224825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
    Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
    Trials; 2015 Nov; 16():496. PubMed ID: 26530718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare's intensive behavioral therapy for obesity: an exploratory cost-effectiveness analysis.
    Hoerger TJ; Crouse WL; Zhuo X; Gregg EW; Albright AL; Zhang P
    Am J Prev Med; 2015 Apr; 48(4):419-25. PubMed ID: 25703178
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.